GlassScriptPhysician profile
Theodore Alan Frank
NPI 1942211164
$50,609.98
in general payments reported to CMS, 2019-2025
17 companies · $9,797 in 2025
The $9,797 reported for 2025 was more than what 94% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $4,993 · 2021: $7,172 · 2022: $12K · 2023: $5,289 · 2024: $466 · 2025: $9,797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Food and Beverage: $1,629 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $400 · Travel and Lodging: $31.00 · Education: $18.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,475.00 |
| Food and Beverage | $1,628.76 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $400.00 |
| Travel and Lodging | $31.00 |
| Education | $18.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $24,143.23 | 2019-2025 | Orenitram, Remodulin |
| Astrazeneca Pharmaceuticals LP | $10,467.80 | 2019-2023 | Farxiga |
| Kestra Medical Technology Services, INC. | $9,625.00 | 2025 | Assure Wcd |
| Merck Sharp & Dohme LLC | $3,642.95 | 2022-2024 | Winrevair |
| Abiomed | $1,091.80 | 2019-2023 | Impella |
| Actelion Pharmaceuticals US, INC. | $304.43 | 2019-2025 | Uptravi, Opsumit |
| Cvrx, INC. | $231.57 | 2022-2024 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $201.24 | 2019-2021 | |
| Vifor Pharma, INC. | $200.00 | 2021 | |
| Abbott Laboratories | $198.60 | 2019-2024 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Amgen INC. | $134.00 | 2019 | |
| Scpharmaceuticals INC. | $125.00 | 2024 | |
| Boston Scientific Corporation | $71.60 | 2019-2023 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $58.31 | 2021-2022 | |
| Novo Nordisk INC | $50.94 | 2021-2023 | Ozempic, Rybelsus |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $48.93 | 2022-2025 | Lifevest |
| Pfizer INC. | $14.58 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Frank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.